You are here

Home » Content

Subklinik Hipertiroidi

Subclinical Hyperthyroidism

Journal Name:

  • Smyrna Tıp Dergisi

Publication Year:

  • 2015

Key Words:

Keywords (Original Language):

Author Name
Abstract (2. Language): 
Subclinical hyperthyroidism is definied that; normal levels of serum free thyroxine (FT4) and free triiodothyronine (FT3) levels with low or undetectable levels of serum thyroid stimulating hormone (TSH) levels. It became from endogenous reasons like Graves and toxic nodular goiter or exogenous reasons like more doses depending on levothyroxine therapy. Subklinik hyperthyroidism is related with increased atrial fibrillation risk in elderly patients and low bone density in postmenopausal women. However, the effect of treatment of subclinical hyperthyroidism to prevent these situtations has not yet been clarified and prospective randomized, controlled trials are needed.
Bookmark/Search this post with
Abstract (Original Language): 
Subklinik hipertiroidi serumda normal düzeydeki serbest tiroksin (sT4) ve serbest triiyodotironin (sT3) düzeylerine, düşük veya ölçülemez düzeydeki serum tiroid stimulan hormon (TSH) düzeyinin eşlik etmesidir. Graves, toksik nodüler guatr gibi endojen veya fazla dozda levotiroksin tedavisine bağlı, eksojen olarak gelişebilir. Subklinik hipertiroidi yaşlı hastalarda artmış atriyal fibrilasyon riski ve postmenopozal kadınlarda düşük kemik dansitesi ile ilişkilidir. Bununla beraber subklinik hipertiroidinin tedavi edilmesinin bu durumları önlemedeki etkisi henüz açıklığa kavuşmamıştır ve prospektif, randomize, kontrollü çalışmalara ihtiyaç bulunmaktadır.
FULL TEXT (PDF): 
PDF icon arastirmax-subklinik-hipertiroidi.pdf
  • 3
52
57
  • Turkish

REFERENCES

References: 

1. Surks
MI
, Ortiz E, Daniels GH, Sawin CT, Col
NF, Cobin RH, Franklyn JA, Hershman JM,
Burman KD, Denke MA, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. Jama 2004; 291:228-38.
Smyrna Tıp Dergisi - 56 -
2. Spencer CA, Takeuchi M, Kazarosyan M, MacKenzie F, Beckett GJ, Wilkinson E: Interlaboratory/intermethod differences in functional sensitivity of immunometric assays of thyrotropin (TSH) and impact on reliability of measurement of subnormal concentrations of TSH. Clinical Chemistry 1995; 41:367-74.
3. Marqusee E, Haden ST, Utiger RD. Subclinical thyrotoxicosis. Endocrinology and metabolism clinics of North America 1998;27:37-49.
4. Aghini-Lombardi F, Antonangeli L, Martino E, Vitti P, Maccherini D, Leoli F, Rago T, Grasso L, Valeriano R, Balestrieri A, Pinchera A. The spectrum of thyroid disorders in an iodine-deficient community: the Pescopagano survey. The Journal of Clinical Endocrinology and Metabolism 1999; 84:561-6.
5. De Whalley P. Do abnormal thyroid stimulating hormone level values result in treatment changes? A study of patients on thyroxine in one general practice. The British Journal of General Practice: The Journal of the Royal College of General Practitioners 1995;45:93-5.
6. Biondi B, Palmieri EA, Klain M, Schlumberger M, Filetti S, Lombardi G. Subclinical hyperthyroidism: clinical features and treatment options. European Journal of Endocrinology
2005;152:1-9.
7. Rosario PW. Natural history of subclinical hyperthyroidism in elderly patients with TSH between 0.1 and 0.4 mIU/l: a prospective study.
Clinical Endocrinology 2010;72:685-8.
8. Rosario PW. The natural history of subclinical hyperthyroidism in patients below the age of 65 years. Clinical Endocrinology 2008;68:491-2.
9. Cooper DS. Approach to the patient with subclinical hyperthyroidism. The Journal of Clinical Endocrinology and Metabolism 2007;
92:3-9.
10. Stanbury JB, Ermans AE, Bourdoux P, Todd C, Oken E, Tonglet R, Vidor G, Braverman LE, Medeiros-Neto G. Iodine-induced hyperthyroidism: occurrence and epidemiology. Thyroid. Official Journal of the American Thyroid Association 1998;8:83-100.
11. Mercuro G, Panzuto MG, Bina A, Leo M, Cabula R, Petrini L, Pigliaru F, Mariotti S. Cardiac function, physical exercise capacity, and quality of life during long-term thyrotropin-suppressive therapy with levothyroxine: effect of individual dose tailoring. The Journal of Clinical Endocrinology and Metabolism 2000;
85:159-64.
12. Biondi B, Palmieri EA, Fazio S, Cosco C, Nocera M, Sacca L, Filetti S, Lombardi G, Perticone F. Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and
middle-aged patients. The Journal of Clinical Endocrinology and Metabolism 2000;85:4701-5.
13. Kalmijn S, Mehta KM, Pols HA, Hofman A, Drexhage HA, Breteler MM. Subclinical hyperthyroidism and the risk of dementia. The Rotterdam study. Clinical Endocrinology 2000;
53:733-7.
14. De Jong FJ, Den Heijer T, Visser TJ, Ee Rijke YB, Drexhage HA, Hofman A, Breteler MM. Thyroid hormones, dementia, and atrophy of the medial temporal lobe. The Journal of Clinical Endocrinology and Metabolism 2006;91:2569-
73.
15. Petretta M, Bonaduce D, Spinelli L, Vicario ML, Nuzzo V, Marciano F, Camuso P, De Sanctis V, Lupoli G. Cardiovascular haemodynamics and cardiac autonomic control in patients with subclinical and overt hyperthyroidism. European Journal of
Endocrinology 2001;145:691-6.
16. Auer J, Scheibner P, Mische T, Langsteger W, Eber O, Eber B. Subclinical hyperthyroidism as a risk factor for atrial fibrillation. American
Heart Journal 2001;142:838-42.
17. Ochs N, Auer R, Bauer DC, Nanchen D, Gussekloo J, Cornuz J, Rodondi N. Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. Annals of Internal Medicine 2008;148:832-45.
18. Haentjens P, Van Meerhaeghe A, Poppe K, Velkeniers B. Subclinical thyroid dysfunction and mortality: an estimate of relative and absolute excess all-cause mortality based on time-to-event data from cohort studies. European Journal of Endocrinology 2008;
159:329-41.
19. Sgarbi JA, Matsumura LK, Kasamatsu TS, Ferreira SR, Maciel RM. Subclinical thyroid dysfunctions are independent risk factors for mortality in a 7.5-year follow-up: the Japanese-Brazilian thyroid study. European Journal of Endocrinology 2010;162:569-77.
20. Ittermann T, Haring R, Sauer S, Wallaschofski H, Dorr M, Nauck M, Volzke H. Decreased serum TSH levels are not associated with mortality in the adult northeast German population. European Journal of Endocrinology
2010;162:579-85.
21. Sgarbi JA, Villaca FG, Garbeline B, Villar HE, Romaldini JH: The effects of early antithyroid therapy for endogenous subclinical hyperthyroidism in clinical and heart abnormalities. The Journal of Clinical Endocrinology and Metabolism 2003;88:1672-
7.
Smyrna Tıp Dergisi - 57 -
22. Faber J, Wiinberg N, Schifter S, Mehlsen J. Haemodynamic changes following treatment of subclinical and overt hyperthyroidism. European Journal of Endocrinology 2001;
145:391-6.
23. Abe
E
, Marians RC, Yu W, Wu XB, Ando T, Li
Y, Iqbal J, Eldeiry L, Rajendren G, Blair HC, et
al. TSH is a negative regulator of skeletal
remodeling. Cell 2003;115:151-62.
24. Rosario PW. Bone and heart abnormalities of subclinical hyperthyroidism in women below the age of 65 years. Arquivos Brasileiros de Endocrinologia e Metabologia 2008;52:1448-
51.
25. Uzzan B, Campos J, Cucherat M, Nony P, Boissel JP, Perret GY. Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis. The Journal of Clinical Endocrinology and Metabolism 1996;81:4278-89.
26. Bauer DC, Ettinger B, Nevitt MC, Stone KL, Study of Osteoporotic Fractures Research G. Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Annals
of Internal Medicine 2001;134:561-8.
27. Sheppard MC, Holder R, Franklyn JA. Levothyroxine treatment and occurrence of fracture of the hip. Archives of Internal
Medicine 2002;162:338-43.
28. Faber J, Jensen IW, Petersen L, Nygaard B, Hegedus L, Siersbaek-Nielsen K. Normalization of serum thyrotrophin by means of radioiodine
treatment in subclinical hyperthyroidism: effect on bone loss in postmenopausal women.
Clinical Endocrinology 1998;48:285-90.
29. Greenlund LJ, Nair KS, Brennan MD. Changes in body composition in women following treatment of overt and subclinical hyperthyroidism. Endocrine Practice 2008;
14:973-8.
30. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver
B, Sherman SI, Tuttle RM, American Thyroid Association Guidelines T. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006;
16:109-42.
31. Biondi B, Cooper DS. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer. Thyroid 2010;
20:135-46.
32. Mudde AH, Houben AJ, Nieuwenhuijzen Kruseman AC. Bone metabolism during anti-thyroid drug treatment of endogenous subclinical hyperthyroidism. Clinical Endocrinology 1994;41:421-4.

Thank you for copying data from http://www.arastirmax.com